†Blood and tissue from injected/noninjected lesions and draining lymph nodes will be collected throughout study for translational analyses..
‡Lerapolturev administered at a dose up to 6x108 TCID50 into up to 6 lesions q3w or q4w.
§IV pembrolizumab q3w or q6w or IV nivolumab q2w or q4w at discretion of the principal investigator.
†Blood and tissue from injected/noninjected lesions and draining lymph nodes will be collected throughout study for translational analyses..
‡Lerapolturev administered at a dose up to 6x108 TCID50 into up to 6 lesions q3w or q4w.
§IV pembrolizumab q3w or q6w or IV nivolumab q2w or q4w at discretion of the principal investigator.
LUMINOS-102 (NCT04577807) is a multicenter, open-label, randomized phase 2 study investigating the efficacy and safety of lerapolturev with or without anti–PD-1 antibodies in patients with unresectable cutaneous or mucosal melanoma with injectable lesions who failed prior anti–PD-1 therapy.
The study enrolled its first patient in March 2021 and is currently ongoing at >20 US sites, with additional sites due to initiate soon.
A completed safety run-in characterized lerapolturev injections in up to 6 lesions/cycle or at a maximum dose of 6x108 TCID50. Randomization (1:1) of 50 patients to receive lerapolturev (Arm 1) or lerapolturev combined with anti–PD-1 (Arm 2) is now underway.
LUMINOS-102 builds on the successful experience with lerapolturev in a previous phase 1 trial as published in the Journal for ImmunoTherapy of Cancer.
Please contact us or email LUMINOS-102@istarioncology.com.
